Immune Checkpoint Inhibitors for the Treatment of Bladder CancerAntonio López-Beltrán, Rodolfo Montironi, Alessia Cimadamore et al.|Cancers|2021Cited by 289
Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotypeJorge Rebola, Antonio López-Beltrán, Vanessa Henriques et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2019Cited by 53
Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression AnalysisAntonio López-Beltrán, Liang Cheng, Ana Blanca et al.|Cancers|2021Cited by 38
T1 bladder carcinoma with variant histology: pathological features and clinical significanceAntonio López-Beltrán, Liang Cheng, Ana Blanca et al.|Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin|2022Cited by 31
Immunotherapy in Renal Cell Carcinoma from Poverty to the Spoiled of ChoiceFrancesco Massari, Antonio López-Beltrán, Vincenzo Di Nunno et al.|Immunotherapy|2019Cited by 18